1
|
Garcia J, Compte A, Galan C, Cozar M, Buxeda M, Mourelo S, Piñeiro T, Soler M, Valls E, Bassa P, Santabarbara J. 18F-choline PET/MR in the initial staging of prostate cancer. Impact on the therapeutic approach. Rev Esp Med Nucl Imagen Mol 2021. [DOI: 10.1016/j.remnie.2020.10.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
2
|
Garcia J, Cozar M, Soler M, Bassa P, Riera E, Buxeda M, Valls E, Ferrer J. Standardization of acquisition protocols using PET/CT with 18F-Choline in prostate cancer. Rev Esp Med Nucl Imagen Mol 2020. [DOI: 10.1016/j.remnie.2020.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Garcia JR, Cozar M, Soler M, Bassa P, Riera E, Buxeda M, Valls E, Ferrer J. Standardization of acquisition protocols using PET/CT with 18F-Choline in prostate cancer. Rev Esp Med Nucl Imagen Mol 2020; 39:204-211. [PMID: 32192907 DOI: 10.1016/j.remn.2020.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Revised: 12/29/2019] [Accepted: 01/07/2020] [Indexed: 11/16/2022]
Abstract
AIM To standardize acquisition protocols for 18F-Choline PET/CT to prevent from urine interference, to determine the best time point for the whole-body study, and to assess whether "dual point" acquisition allows for differentiating malignant vs. benign lesions. METHODS One hundred consecutive patients with prostate cancer were prospectively studied. Immediately after 18F-Choline injection, a pelvis study was acquired, and a whole-body was subsequently obtained 1 and 2 hours p.i. Mean SUVmax was obtained in regions and for every sequential imaging. Mean analysis (χ2) and SUV percentage change (2/1 hours; 1 hours/0 min) were obtained. Metabolic pattern dynamics were assessed: accumulative vs. clearance. Patient follow-up after therapy and directed classification whenever ethically possible were performed. RESULTS Fifty-three prostate foci, without disturbing urinary activity was ever found on early images. Accumulative pattern in 42, with percentage increase was: 0 min/1 hour: +16.7% (χ20.94); 1/2 hours: +10,0% (χ2 0.83). Clearance pattern in 11, with percentage decrease: 0 min/1 hour: -21.4% (χ20.91): -7.7% (χ20.85), corresponding in 7 to initial staging and in 4 post-radiotherapy biochemical recurrence. Every infradiaphragmatic uptake (n: 24) showed accumulative pattern, with percentage increase of +9.1% (χ20.97), all of them depicted on early imaging. As for 12 supradiaphragmantic uptake, 8 of them showed clearance pattern with percentage decrease: -13.0% (χ20.95). Accumulative pattern showed in 4 of them with percentage increase +13.0% (χ2 0.96), thus being assessed as invasive/malignant. Every bone uptake (n: 18) showed accumulative pattern, with percentage increase: +17.1% (χ20.95), all of them depicted on 1 hour imaging. CONCLUSIONS As for prostate assessment is concerned, dual point at 0 min/1 hour proved to be the best procedure. As for supradiaphragmatic lymph-nodes detection, dual point with 1/2 hours performed best. As for infradiaphragmatic and bone involvement, as well as for inconclusive findings, the 2 hour imaging increased our diagnostic confidence.
Collapse
Affiliation(s)
- J R Garcia
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España.
| | - M Cozar
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| | - M Soler
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| | - P Bassa
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| | - E Riera
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| | - M Buxeda
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| | - E Valls
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| | - J Ferrer
- Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, España
| |
Collapse
|
4
|
Pineda-Cirera L, Cabana-Domínguez J, Roncero C, Cozar M, Grau-López L, Abad AC, Martínez-Luna N, Robles-Martínez M, Sánchez-Mora C, Ramos-Quiroga JA, Casas M, Ribasés M, Fernàndez-Castillo N, Cormand B. Corrigendum to "Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample" [Drug Alcohol Depend. 187 (2018) 358-362]. Drug Alcohol Depend 2020; 208:107844. [PMID: 31945704 DOI: 10.1016/j.drugalcdep.2020.107844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Laura Pineda-Cirera
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Catalonia, Spain
| | - Judit Cabana-Domínguez
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Catalonia, Spain
| | - Carlos Roncero
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain; Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Psychiatric Service, University of Salamanca Health Care Complex and Institute of Biomedicine of Salamanca, University of Salamanca, Castile and Leon, Spain
| | - Mònica Cozar
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Catalonia, Spain
| | - Lara Grau-López
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain; Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain
| | - Alfonso C Abad
- Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain
| | - Nieves Martínez-Luna
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain; Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain
| | - María Robles-Martínez
- Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain
| | - Cristina Sánchez-Mora
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
| | - Josep Antoni Ramos-Quiroga
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain; Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
| | - Miquel Casas
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain
| | - Marta Ribasés
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035, Barcelona, Catalonia, Spain; Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
| | - Noèlia Fernàndez-Castillo
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Catalonia, Spain.
| | - Bru Cormand
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028, Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Catalonia, Spain.
| |
Collapse
|
5
|
Roca-Ayats N, Falcó-Mascaró M, García-Giralt N, Cozar M, Abril JF, Quesada-Gómez JM, Prieto-Alhambra D, Nogués X, Mellibovsky L, Díez-Pérez A, Grinberg D, Balcells S. Estudio genético de la fractura femoral atípica mediante la secuenciación del exoma en tres hermanas afectas y tres pacientes no relacionadas. Rev Osteoporos Metab Miner 2018. [DOI: 10.4321/s1889-836x2018000400002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
|
6
|
Pineda-Cirera L, Cabana-Domínguez J, Roncero C, Cozar M, Grau-López L, Abad AC, Martínez-Luna N, Robles-Martínez M, Sánchez-Mora C, Ramos-Quiroga JA, Casas M, Ribasés M, Fernàndez-Castillo N, Cormand B. Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample. Drug Alcohol Depend 2018; 187:358-362. [PMID: 29715653 DOI: 10.1016/j.drugalcdep.2018.03.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Revised: 03/02/2018] [Accepted: 03/08/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND Substance dependence is a chronic and relapsing disorder explained by genetic and environmental risk factors. The aim of our study is to replicate previous genome-wide significant (GWS) hits identified in substance dependence in general or in cocaine dependence in particular using an independent sample from Spain. METHODS We evaluated, in a Spanish sample of 1711 subjects with substance dependence (1011 of them cocaine dependent) and 1719 control individuals, three SNPs identified as GWS in previous studies: rs1868152 and rs2952621 (located near LINC02052 and LINC01854, respectively), associated with substance dependence, and rs2629540 (in the first intron of FAM53B), associated with cocaine dependence. RESULTS We replicated the association between rs2952621 and substance dependence under the dominant model (P = 0.020), with the risk allele (T) being the same in our sample and in those two reported previously. We then performed a meta-analysis of the two samples used in the original study that reported the association of rs2952621 with substance dependence (Collaborative Studies on Genetics of Alcoholism (COGA) and Study of Addiction: Genetics and Environment (SAGE)) together with our Spanish sample. The meta-analysis of 3747 cases and 4043 controls confirmed the association (OR = 1.26, 95% CI = 1.15-1.39). CONCLUSIONS The rs2952621 variant, located downstream from the yet uncharacterized gene LINC01854, is associated with substance dependence in our Spanish sample. Further research is needed to understand its contribution to the susceptibility to substance dependence.
Collapse
Affiliation(s)
- Laura Pineda-Cirera
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950 Esplugues de Llobregat, Barcelona, Catalonia, Spain
| | - Judit Cabana-Domínguez
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950 Esplugues de Llobregat, Barcelona, Catalonia, Spain
| | - Carlos Roncero
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain; Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029 Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Psychiatric Service, University of Salamanca Health Care Complex and Institute of Biomedicine of Salamanca, University of Salamanca, Castile and Leon, Spain
| | - Mònica Cozar
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950 Esplugues de Llobregat, Barcelona, Catalonia, Spain
| | - Lara Grau-López
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain; Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029 Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain
| | - Alfonso C Abad
- Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain
| | - Nieves Martínez-Luna
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain; Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain
| | - María Robles-Martínez
- Addiction and Dual Diagnosis Unit, Psychiatric Services, Hospital Universitari Vall d'Hebron-ASPB, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain
| | - Cristina Sánchez-Mora
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029 Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - Josep Antoni Ramos-Quiroga
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029 Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain; Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - Miquel Casas
- Psychiatry Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029 Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain
| | - Marta Ribasés
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029 Madrid, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Edifici Mediterrània, 08035 Barcelona, Catalonia, Spain; Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - Noèlia Fernàndez-Castillo
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950 Esplugues de Llobregat, Barcelona, Catalonia, Spain.
| | - Bru Cormand
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Av. Monforte de Lemos 3-5, Pabellón 11, 280029, Madrid, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Passeig de Sant Joan de Déu 2, 08950 Esplugues de Llobregat, Barcelona, Catalonia, Spain.
| |
Collapse
|
7
|
Cammarata-Scalisi F, Stock F, Avendaño A, Cozar M, Balcells S, Grinberg D. [Clinical and molecular study in a family with multiple osteochondromatosis]. Acta Ortop Mex 2018; 32:108-111. [PMID: 30182558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
We present two cases of a family with the diagnosis of multiple osteochondromatosis, which was confirmed by molecular study with nonsense in heterozygosis mutation c.1219CT, (p.Gln407Stop) in the EXT1 gene. In these cases, the Madelung deformity was presented in one patient as an uncommon finding and chondrosarcoma as a feared complication in the other case, highlighting intrafamilial variation, which is why individual and interdisciplinary evaluation is recommended. In addition, before a genetic entity should provide adequate and timely family genetic counseling to all its members.
Collapse
Affiliation(s)
- F Cammarata-Scalisi
- Unidad de Genética Médica. Departamento de Puericultura y Pediatría. Facultad de Medicina. Universidad de Los Andes. Mérida, Venezuela
| | - F Stock
- Unidad de Oncología Pediátrica. Instituto Autónomo Hospital Universitario de Los Andes. Mérida, Venezuela
| | - A Avendaño
- Unidad de Genética Médica. Departamento de Puericultura y Pediatría. Facultad de Medicina. Universidad de Los Andes. Mérida, Venezuela
| | - M Cozar
- Departamento de Genética. Facultad de Biología. Universidad de Barcelona. CIBERER, IBUB. Barcelona, España
| | - S Balcells
- Departamento de Genética. Facultad de Biología. Universidad de Barcelona. CIBERER, IBUB. Barcelona, España
| | - D Grinberg
- Departamento de Genética. Facultad de Biología. Universidad de Barcelona. CIBERER, IBUB. Barcelona, España
| |
Collapse
|
8
|
Garcia J, Cozar M, Baquero M, Fernández Barrionuevo J, Jaramillo A, Rubio J, Maida G, Soler M, Riera E. The value of 11 C-methionine PET in the early differentiation between tumor recurrence and radionecrosis in patients treated for a high-grade glioma and indeterminate MRI. Rev Esp Med Nucl Imagen Mol 2017. [DOI: 10.1016/j.remnie.2016.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Garcia J, Villasboas-Rosciolesi D, Soler M, Bassa P, Cozar M, Riera E. Peritoneal Cancer Index by 18 F-FDG PET/TC pre and post-hyperthermic intraperitoneal chemotherapy. Report of a case. Rev Esp Med Nucl Imagen Mol 2016. [DOI: 10.1016/j.remnie.2016.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Garcia JR, Cozar M, Baquero M, Fernández Barrionuevo JM, Jaramillo A, Rubio J, Maida G, Soler M, Riera E. The value of 11C-methionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a high-grade glioma and indeterminate MRI. Rev Esp Med Nucl Imagen Mol 2016; 36:85-90. [PMID: 27503425 DOI: 10.1016/j.remn.2016.06.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2016] [Revised: 05/30/2016] [Accepted: 06/06/2016] [Indexed: 10/21/2022]
Abstract
OBJECTIVE To evaluate the contribution of 11C-Methionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a high grade glioma. METHOD The study included 30 patients with glioma (III/IV grade) treated with surgery/radiotherapy/chemotherapy (5-8 months) and with an indeterminate MRI. All patients underwent a 11C-Methione PET (within 15 days of MRI) and studies were visually analysed (intensity and morphology of uptake), quantified (SUV max/SUV mean background), and coregistered to MRI (3D-Flair). Patient management was decided by the neuro-oncology committee to clinical and imaging follow-up, second-line treatment, or surgery. RESULTS There were 23 11C-Methionine PET studies visually positive. Morphology of uptake was focal in 15, diffuse in 4, and ring-shaped in 4. Three out of the focal uptake cases underwent resection (Histopathology +). Sixteen underwent second-line therapy (11 responded; 5 progressed). The 4 cases with ring-shaped uptake were followed-up, and progression was found in 2 (true-positive), and disease-free in 2 (follow-up of 6 and 7 months, respectively) (false-positive). Seven out of 11C-Methionine studies PET were visually negative, and all of them were disease-free (follow-up of 3-12 months). SUV lesion/background was 2.79±1.35 in tumour recurrence, and 1.53±0.39 in radionecrosis (P<.05). Taking into account a SUV lesion/background threshold of 2.35, the sensitivity and specificity values were 90.5% and 100%, respectively. CONCLUSION Visual analysis, quantitative and PET/MRI coregistration of 11C-Methionine PET showed their complementary role in patients with indeterminate MRI results, thus allowing early differentiation between tumour recurrence and radionecrosis, and helping in the individual therapy approach.
Collapse
Affiliation(s)
- J R Garcia
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España.
| | - M Cozar
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| | - M Baquero
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| | | | - A Jaramillo
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| | - J Rubio
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| | - G Maida
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| | - M Soler
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| | - E Riera
- CETIR Unidad PET, CETIR-ERESA, Esplugues, Barcelona, España
| |
Collapse
|
11
|
García J, Cozar M, Soler M, Bassa P, Riera E, Ferrer J. Salvage radiotherapy in prostate cancer patients. Planning, treatment response and prognosis using 11 C-choline PET/CT. Rev Esp Med Nucl Imagen Mol 2016. [DOI: 10.1016/j.remnie.2016.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Garcia JR, Villasboas-Rosciolesi D, Soler M, Bassa P, Cozar M, Riera E. Peritoneal Cancer Index by (18)F-FDG PET/TC pre and post-hyperthermic intraperitoneal chemotherapy. Report of a case. Rev Esp Med Nucl Imagen Mol 2016; 35:329-31. [PMID: 27036888 DOI: 10.1016/j.remn.2016.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Revised: 02/17/2016] [Accepted: 02/18/2016] [Indexed: 11/24/2022]
Abstract
Radical cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy increases survival in patients with end-stage peritoneal carcinomatosis, and who are under palliative therapy. The Peritoneal Cancer Index enables the tumor burden to be quantified during surgery, as well as treatment planning and patient prognosis. It is obtained by combining the tumor spread in 13 abdominal and pelvic regions with the largest tumor size. Fluorodeoxyglucose positron emission tomography/computed tomography is the technique of choice for those patients selected to undergo radical cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy, due to its higher detection rate of carcinomatosis, and since it allows extra-peritoneal disease staging. The simplified Peritoneal Cancer Index (9 regions defined by 2 transverse and 2 sagittal planes) obtained by fluorodeoxyglucose positron emission tomography/computed tomography allows correlation with the surgical procedure, therefore its standardization is advisable.
Collapse
Affiliation(s)
- J R Garcia
- Unidad PET, CETIR-ERESA, Esplugues de Llobregat, Barcelona, España.
| | | | - M Soler
- Unidad PET, CETIR-ERESA, Esplugues de Llobregat, Barcelona, España
| | - P Bassa
- Unidad PET, CETIR-ERESA, Esplugues de Llobregat, Barcelona, España
| | - M Cozar
- Unidad PET, CETIR-ERESA, Esplugues de Llobregat, Barcelona, España
| | - E Riera
- Unidad PET, CETIR-ERESA, Esplugues de Llobregat, Barcelona, España
| |
Collapse
|
13
|
García JR, Cozar M, Soler M, Bassa P, Riera E, Ferrer J. Salvage radiotherapy in prostate cancer patients. Planning, treatment response and prognosis using (11)C-choline PET/CT. Rev Esp Med Nucl Imagen Mol 2016; 35:238-45. [PMID: 26803491 DOI: 10.1016/j.remn.2015.11.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Revised: 11/19/2015] [Accepted: 11/22/2015] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To assess the prognostic value of the therapeutic response by (11)C-choline PET/CT in prostate cancer patients with biochemical recurrence in which (11)C-choline PET/CT indicated radio-guided radiotherapy. METHODS The study included 37 patients initially treated with prostatectomy, who were treated due to biochemical recurrence. (11)C-choline PE/CT detected infra-diaphragmatic lymph-node involvement. All were selected for intensity modulated radiation therapy, escalating the dose according to the PET findings. One year after treatment patients underwent PSA and (11)C-choline PET/CT categorizing response (complete/partial/progression). Clinical/biochemical/image monitoring was performed until appearance of second relapse or 36 months in disease-free patients. RESULTS (11)C-choline PET/CT could detect lymph nodes in all 37 patients. They were 18 (48.6%) of more than a centimetre in size and 19 (51.3%) with no pathological CT morphology: 9 (24.3%) with positive lymph nodes of around one centimetre and 10 (27.0%) only less than a centimetre in size. The response by (11)C-choline PET/CT was categorised one year after radiotherapy: 16 patients (43.2%) complete response; 15 (40.5%) partial response, and 6 (16.2%) progression. The response was concordant between the PSA result and (11)C-choline PET/CT in 32 patients (86.5%), and discordant in five (13.5%). New recurrence was detected in 12 patients (80%) with partial response, and 5 (31.2%) with complete response. The mean time to recurrence was 9 months after partial response, and 18 months after complete response (significant difference, p<.0001). CONCLUSION (11)C-choline PET/CT allows the selection of patients with recurrent prostate cancer candidates for radiotherapy and to plan the technique. The evaluation of therapeutic response by (11)C-choline PET/CT has prognostic significance.
Collapse
Affiliation(s)
- J R García
- Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España.
| | - M Cozar
- Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España
| | - M Soler
- Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España
| | - P Bassa
- Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España
| | - E Riera
- Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España
| | - J Ferrer
- Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España
| |
Collapse
|
14
|
Garcia J, Romera N, Cozar M, Soler M, Moragas M, Escobar M. 11C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.acuroe.2015.03.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Garcia J, Romera N, Cozar M, Soler M, Moragas M, Escobar M. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. Actas Urol Esp 2015; 39:259-63. [PMID: 25454265 DOI: 10.1016/j.acuro.2014.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Revised: 10/09/2014] [Accepted: 10/10/2014] [Indexed: 10/24/2022]
Abstract
CLINIC PROBLEM AND CASE SERIES To assess the diagnostic usefulness of (11)C-choline PET/CT vs. multi-parametric MRI in the prostate cancer relapse. A retrospective study of 21 patients with prostate cancer treated initially with surgery (n=12), radiotherapy (n=9). PSA levels were increased (post-surgery: .3-3.6 ng/ml; post-radiotherapy: 2.4-8.8 ng/ml). In an interval of time of 15 days all patients were underwent to: whole-body-dual-modality PET-CT carried out early after (11)C-choline (296 ± 29 MBq) injection, and multiparametric prostate MRI with paramagnetic intravenous contrast (using anatomical imaging sequences, diffusion-weighted imaging and dynamic contrast-enhanced imaging). On the basis of our results, all patients were underwent to directed diagnosis and/or clinical, analytic and imaging follow-up. In 15 patients (71.4%) both procedures showed concordant results: 4 negative and 11 positive cases [7 local recurrences, 3 isolated pelvic lymph nodes (2 infracentimetric), 1 local relapse and only one M1 bone metastases]. The results were discordant in 6 patients (28.6%): 3 local relapses in MRI with no PET significance, 1 local relapse in PET with no MRI significance. 2 bone metastases were identified with PET (out of the field-of-view of MRI). COMMENT (11)C-choline PET/CT and multi-parametric MRI play a complementary role in the detection of local relapse in prostate cancer patients, with similar sensitivity for the detection of lymph involvement. Whole-body 11C-choline PET/CT technique is also useful for bone staging.
Collapse
|
16
|
Mavridou I, Cozar M, Douzgou S, Xaidara A, Lianou D, Vanier M, Dimitriou E, Grinberg D, Vilageliu L, Michelakakis H. Niemann-Pick type C disease: a novelNPC1mutation segregating in a Greek island. Clin Genet 2013; 85:543-7. [DOI: 10.1111/cge.12200] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 05/17/2013] [Accepted: 05/17/2013] [Indexed: 11/30/2022]
Affiliation(s)
- I. Mavridou
- Department of Enzymology and Cellular Function; Institute of Child Health; Athens Greece
| | - M. Cozar
- Department de Genetica, Facultat de Biologia; Universitat de Barcelona, CIBERER, IBUB; Barcelona Spain
| | - S. Douzgou
- Department of Enzymology and Cellular Function; Institute of Child Health; Athens Greece
| | - A. Xaidara
- First Department of Pediatrics, ‘Aghia Sophia’ Children's Hospital; University of Athens; Athens Greece
| | - D. Lianou
- First Pediatric Clinic; ‘Aghia Sophia’ Children's Hospital; Athens Greece
| | - M.T. Vanier
- Laboratoire Gillet-Mérieux, CBPE; Hôpital Lyon-Est, Hôpitaux de Lyon; Lyon France
| | - E. Dimitriou
- Department of Enzymology and Cellular Function; Institute of Child Health; Athens Greece
| | - D. Grinberg
- Department de Genetica, Facultat de Biologia; Universitat de Barcelona, CIBERER, IBUB; Barcelona Spain
| | - L. Vilageliu
- Department de Genetica, Facultat de Biologia; Universitat de Barcelona, CIBERER, IBUB; Barcelona Spain
| | - H. Michelakakis
- Department of Enzymology and Cellular Function; Institute of Child Health; Athens Greece
| |
Collapse
|
17
|
Urreizti R, Moya-García AA, Pino-Ángeles A, Cozar M, Langkilde A, Fanhoe U, Esteves C, Arribas J, Vilaseca MA, Pérez-Dueñas B, Pineda M, González V, Artuch R, Baldellou A, Vilarinho L, Fowler B, Ribes A, Sánchez-Jiménez F, Grinberg D, Balcells S. Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency. Clin Genet 2010; 78:441-8. [DOI: 10.1111/j.1399-0004.2010.01391.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Díaz-Font A, Santamaría R, Cozar M, Blanco M, Chamoles N, Coll MJ, Chabás A, Vilageliu L, Grinberg D. Clinical and mutational characterization of three patients with multiple sulfatase deficiency: report of a new splicing mutation. Mol Genet Metab 2005; 86:206-11. [PMID: 16125993 DOI: 10.1016/j.ymgme.2005.07.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2005] [Accepted: 07/12/2005] [Indexed: 10/25/2022]
Abstract
Multiple sulfatase deficiency (MSD) is a rare autosomal recessive lysosomal storage disease characterized by impaired activity of all known sulfatases. The gene SUMF1, recently identified, encodes the enzyme responsible for post-translational modification of a cysteine residue, which is essential for the activity of sulfatases. Fewer than 30 MSD patients have been reported to date and 23 different mutations in the SUMF1 gene have been identified. Here, we present the characterization of the mutant alleles of two Spanish and one Argentinean MSD patients. While the two Spanish patients were homozygous for the previously described mutations, c.463T>C (p.S155P) and c.1033C>T (p.R345C), the Argentinean patient was homozygous for the new mutation IVS7+5 G>T. A minigene approach was used to analyze the effect of the splice site mutation identified, due to the lack of sample from the patient. This experiment showed that this change altered the normal splicing of the RNA, which strongly suggests that this is the molecular cause of the disease in this patient.
Collapse
Affiliation(s)
- Anna Díaz-Font
- Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Starting from a pellet of beef brain myelin insoluble in chloroform/methanol (2:1, vol/vol)(Wolfgram protein fraction), a pure W2 protein with apparent molecular weight of 52,000 was isolated by a simple preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis method. A comparative chemical analysis was carried out between purified W2 and a standard tubulin. Glutamic acid and arginine were the N-terminals detected. Similar peptide maps and amino acid composition were also found in both proteins. Immunological cross-reactivity was detected when W2 protein was tested against antitubulin serum. These results suggest that W2 protein could have a tubulin-like protein nature that is associated with the myelin membrane and could play a role in the myelination process.
Collapse
|